CannabisNewsBreaks – AmeriCann (ACAN) Announces Positive Quarterly Results, Operations Update

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today released financial and operational results for its fiscal quarter ending March 31, 2022. According to the update, the company achieved a significant increase in year-over-year quarterly revenue, culminating in positive net income for the quarter. Revenue from operations increased over 52% for the quarter ended March 2022 relative to the same quarter in 2021, an increase of $230,021. AmeriCann set an all-time monthly record in revenue for April 2022 and attributes the increase in financial performance to greater revenue received from products produced and manufactured at Building 1, the company’s initial building at its Massachusetts Cannabis Center development in Freetown, Massachusetts. “The success we have achieved with Building 1 is a testament to the quality of consistent products being produced for patients and consumers,” said AmeriCann CEO and President Tim Keogh. “The increased revenue, margins and profits we have achieved validates our vision for the Massachusetts Cannabis Center and our expansion plans.”

To view the full press release, visit https://cnw.fm/3aSiK

About AmeriCann

AmeriCann develops and leases cannabis cultivation, processing and product manufacturing facilities. AmeriCann uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights, and utility bills are up to 75% less than in typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP-Certified cannabis extraction and product manufacturing infrastructure. AmeriCann has secured licenses to produce cannabis-infused products including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, visit www.AmeriCann.co.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.